Peg Rusconi

Caffeinated. Optimist. Runner. Proud to support biotech + life science.

[Dan Hoard @Dan_Hoard]

Five observations from #Bengals practice:
1. Joe Burrow stayed after practice to throw numerous deep balls and varied the trajectory and velocity.
“His throws are perfect, honestly,” said rookie WR Colbie Young. “He’s one of the best quarterbacks in the league and the way he takes time out of his day to perfect his craft just shows the effort he puts in to win.”

[Dan Hoard @Dan_Hoard]

Dexter Freaking Lawrence.
Ballsy Freaking Move

[Peg Rusconi @PegRusconi]

@Dan_Hoard @CincyLight Sublime camera work…

[EASLnews @EASLnews]

@NoureddinMD presents results from the 96-week Phase 2b SYMMETRY study at #EASLCongress.
Analysis of the effects of efruxifermin at 36 and 96 weeks indicates that longer treatment resulted in more patients with cirrhosis reversal. Efruxifermin was also associated with improvements in liver and metabolic health based on non-invasive tests. Efruxifermin was generally well-tolerated, with transient, mild or moderate gastrointestinal adverse events reported most frequently.

“The topline data from the Phase 2b SYMMETRY trial represents a pivotal moment in liver disease treatment, with efruxifermin becoming the first and only drug to demonstrate a reversal of cirrhosis due to MASH,” said Mazen Nourredin, M.D., Professor of Medicine and Transplant Hepatologist at Houston Methodist Hospital, and principal investigator for the SYMMETRY study. “This breakthrough has the potential to transform the treatment of MASH by bringing the first effective therapeutic for compensated cirrhosis within reach.

@AleksanderKrag @DebbieShawcros1 @EASLedu

[Newhouse School @NewhouseSU]

Tonight, @NewhouseSU and @NewhouseSports honored Dan Hoard '85 with the Glickman Award for Leadership in Sports Media. Congratulations, Dan and thank you also for taking the time to speak with students! #newhousenetwork

[Peg Rusconi @PegRusconi]

@AmberTongPW @endpts @JohnCendpts @arsalanarif @FT @ArmstrongDrew @MaxGelman @ZacharyBrennan @Nicole_DeFeudis @reynaldendpts @jaimy_lee @leilei_wuu @Jared_Whitlock @AndrewE_Dunn @RLCscienceboss @Ayisha_Sharma97 @annajbwn @maxonwifi @NicoleWetsman @lydiapflanzer @ShelbyJLiv @nyeungs @NatalieGrover All the best to you @AmberTongPW !

[Peg Rusconi @PegRusconi]

@AGKootenay Wishing you all the best @AGKootenay !

[Peg Rusconi @PegRusconi]

@graeters @Dan_Hoard Yes please

[Peg Rusconi @PegRusconi]

@maxonwifi Congrats, Max, on some great work and your next chapter.

[Cincinnati Bengals @Bengals]

Ted Karras has devoted his time to creating @CincyHat as a way to fund and work with the Village of Merici, a neighborhood for adults with developmental disabilities.

This is the story of @_teddy_k's Cincy Hats ⬇️

#WPMOYChallenge | @Nationwide

[Cincinnati Bengals @Bengals]

"NOOOOOBODYYY"

[Peg Rusconi @PegRusconi]

SEISMIC #CINatSF #whodey 🐅

[Cincinnati Bengals @Bengals]

Let's 🤬 Go.

[Ja’MarrChase @Real10jayy__]

7/11

[Cincinnati Bengals @Bengals]

WHO DEY!

[Cincinnati Bengals @Bengals]

Always 🤬 open.

[Chroma Medicine @chromamedicine]

At #ASGCT23 Sahar Abubucker just presented data underlining a key advantage of our platform: multiplexing without genomic rearrangements. Time for another 🧵.
1/6

#EpigeneticEditing #Tweetorial

[Chroma Medicine @chromamedicine]

Thrilled to be presenting groundbreaking data today at #ASGCT23 demonstrating the power of harnessing an endogenous system to regulate gene expression. Check out this thread to learn how we did it. 🧵
1/7

#EpigeneticEditing #Tweetorial

[Peg Rusconi @PegRusconi]

.@Bengals social media brilliance #WhoDey 🐅

[Cincinnati Bengals @Bengals]

.@ZEUS__57 and @AftabPureval with an important message...

📺: May 11, 8 PM | NFLNetwork | NFL+

[Genetic Engineering & Biotechnology News @GENbio]

Whole Genome Sequencing for Cancer Arrives in the U.S. with Genome Insight

Genome Insight launches CancerVision in the U.S., a whole #genomesequencing approach to offer actionable insights in #cancer care. Learn more: https://t.co/qdpxaWF7ar

[Chroma Medicine @chromamedicine]

Our CEO Catherine Stehman-Breen had a great conversation recently with @ldtimmerman about Chroma's progress, the future of epigenetic editing, and Catherine's personal journey from academic medicine to a career in biotech. Listen to The Long Run podcast: https://t.co/3MUgHTwL6i